國際新聞精選周六（2017年1月7日）

2017年1月7日 | Filed under: | Posted by: 編輯 D

Novartis adds to its cardio pipeline with $1.65B Ionis pact

Novartis is making a big bet on two of Ionis’ cardio drugs.?The pharma giant $NVS is handing over $225 million in near-term payments, split between fees, an upfront and an equity stake, and promising $1.13 billion more in development and commercialization milestones for a worldwide option and collaboration pact on AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx — handled by Ionis’ subsidiary Akcea.【閱讀全文】

Biotech Patent Dispute Between Academics That Is Far From Academic

On December 6, 2016, the parties to the complex and soon-to-be departed world of patent interferences orally argued their positions on motions in what has been described as the “biotech trial of the century” and as “the biggest biotech patent case in memory.”[1] The parties’ oral arguments mirrored their motions, the most important of which rest on whether the senior party’s invention of the gene-editing system CRISPR-Cas9 in bacteria (i.e. prokaryotic cells) rendered obvious the use of the system in higher organisms (i.e. eukaryotic cells), such as those of humans. The groundbreaking system “has the potential to treat serious human genetic disorders and create designer crops that resist drought and pathogens”[2] and to reap billions for the victor. The PTAB’s decisions on motions might terminate the interference without a priority phase. In any event, absent a settlement between the academic contestants like that between the Pasteur Institute and the National Cancer Institute over who first discovered the cause of AIDS,[3] a higher authority than the PTAB will probably provide the final decision in this monumental dispute.【閱讀全文】

Select small caps stand out amid wider 2016 stock market declines

Small cap drug developers were certainly not immune to the collapse in investor support that ravaged their larger rivals last year, but at least this section of the industry managed to generate some returns for shareholders. Actelion, Genmab, Exelixis and Tesaro can count themselves as some of the standout success stories on the stock market in 2016.【閱讀全文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書面授權(quán)。
★更多深度解析訪問《美中藥源》~

★ 請(qǐng)關(guān)注《美中藥源》微信公眾號(hào) ★